Avita Medical (RCEL)
(Real Time Quote from BATS)
$9.72 USD
+0.05 (0.52%)
Updated Jul 22, 2024 03:00 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RCEL 9.72 +0.05(0.52%)
Will RCEL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RCEL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RCEL
Avita (RCEL) Falls 19% on Lowered 2023 Revenue Guidance
Strength Seen in Avita Medical Inc. (RCEL): Can Its 20.4% Jump Turn into More Strength?
RCEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
AVITA (RCEL) Gets FDA Nod for Expanded Use of RECELL System
Here's Why Momentum in Avita Medical Inc. (RCEL) Should Keep going
Indaptus (INDP) Surges on Upbeat Pre-Clinical Decoy Data
Other News for RCEL
AVITA Medical to Announce Second Quarter 2024 Financial Results
AVITA Medical Appoints Nicole Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary
Avita Medical Shareholders Support Leadership and Strategy
AVITA Medical Achieves Milestone with First Case Using RECELL GO
Commit To Buy AVITA Medical At $7.50, Earn 81.1% Annualized Using Options